Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;12(2):217-229.
doi: 10.1007/s12687-021-00521-8. Epub 2021 Mar 17.

European Reference Networks: challenges and opportunities

Affiliations

European Reference Networks: challenges and opportunities

Birute Tumiene et al. J Community Genet. 2021 Apr.

Abstract

European Reference Networks (ERNs) were founded on the principle that many rare disease (RD) issues are pan-European and any single Member State cannot solve them alone. In 2021, ERNs are already in the deployment stage; however, their day-to-day functioning and realization of their potential are still severely hampered by many challenges, including issues in governance and regulation, lack of legal status, insufficient and unsustainable funding, lack of ERN integration into national systems, endangered collaboration with UK RD experts due to Brexit, insufficient exploitation of ERN potential in RD research, underappreciation of highly qualified human resources, problems with the involvement of patient representatives, and still unclear place of ERNs in the overall European RD and digital ecosystem. Bold and innovative solutions that must be taken to solve these challenges inevitably involve pan-European collaboration across several sectors and among multistakeholder RD communities and in many cases crucially rely on the constructive dialogue and coherent, united decisions of national and European authorities that are based on common EU values. Importantly, unresolved challenges may have a strong impact on the further sustainability of ERNs and their ability to realize full potential in addressing huge unmet needs of RD patients and their families.

PubMed Disclaimer

Conflict of interest statement

Dr. Graessner received consulting fees from Roche. He has received a speaker honorarium from Takeda. The co-authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.

Similar articles

Cited by

References

    1. Bertier G, Cambon-Thomsen A, Joly Y. Is it research or is it clinical? Revisiting an old frontier through the lens of next-generation sequencing technologies. Eur J Med Genet. 2018;61(10):634–641. doi: 10.1016/j.ejmg.2018.04.009. - DOI - PubMed
    1. Commission Delegated Decision of 10 March 2014 setting out criteria and conditions that European Reference Networks and healthcare providers wishing to join a European Reference Network must fulfil (2014). Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32014D0286
    1. Commission Implementing Decision of 10 March 2014 setting out criteria for establishing and evaluating European Reference Networks and their members and for facilitating the exchange of information and expertise on establishing and evaluating such Networks (2014). Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ%3AJOL_2014_147_R_...
    1. Derbel O, Heudel PE, Cropet C, et al. Survival impact of centralization and clinical guidelines for soft tissue sarcoma (a prospective and exhaustive population-based cohort) PLoS One. 2017;12(2):e0158406. doi: 10.1371/journal.pone.0158406. - DOI - PMC - PubMed
    1. European Commission website. European Reference Networks (n.d.) Available at: https://ec.europa.eu/health/ern_en. Accessed 5 Aug 2020

LinkOut - more resources